1. Home
  2. SCHL vs IMMX Comparison

SCHL vs IMMX Comparison

Compare SCHL & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholastic Corporation

SCHL

Scholastic Corporation

HOLD

Current Price

$34.91

Market Cap

672.6M

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$12.13

Market Cap

716.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCHL
IMMX
Founded
1920
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Books
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.6M
716.2M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
SCHL
IMMX
Price
$34.91
$12.13
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$40.00
$19.20
AVG Volume (30 Days)
258.0K
1.5M
Earning Date
03-19-2026
05-08-2026
Dividend Yield
1.99%
N/A
EPS Growth
3442.86
N/A
EPS
2.34
N/A
Revenue
$1,487,100,000.00
N/A
Revenue This Year
$1.88
N/A
Revenue Next Year
$4.05
N/A
P/E Ratio
$14.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.69
$1.94
52 Week High
$48.07
$15.10

Technical Indicators

Market Signals
Indicator
SCHL
IMMX
Relative Strength Index (RSI) 28.93 47.68
Support Level $32.81 $7.96
Resistance Level $36.00 $15.10
Average True Range (ATR) 1.53 0.83
MACD -0.29 -0.33
Stochastic Oscillator 11.37 9.40

Price Performance

Historical Comparison
SCHL
IMMX

About SCHL Scholastic Corporation

Scholastic Corp is a publisher and distributor of children's books, a provider of print and digital instructional materials for grades pre-kindergarten (pre-K) to grade 12 and a producer of entertaining literary and educational children's media. The company creates quality print, digital and audio books, learning materials and programs, classroom magazines and other products that, in combination, offer children, families and educators engaging and comprehensive solutions to support children's learning and reading both at home and at school. It categorizes its businesses into four reportable segments: Children's Book Publishing and Distribution; Education; Entertainment; and International. It derives the majority of revenue from Children's Book Publishing and Distribution segment.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: